NEW YORK, July 29, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Impax Laboratories Inc. ("Impax Laboratories" or the "Company") (NasdaqGS: IPXL -News). Such investors are advised to contact Edward N. Gewirtz or his investor relation's coordinator Eitan Kimelman at email@example.com or 212-697-6484. The investigation focuses on whether the Company and certain of its executives violated federal securities laws. On July 29, 2014, Impax Laboratories announced in a regulatory filing, "receipt of a Form 483 from the U.S. Food and Drug Administration (the "FDA") related to the FDA's inspection of the Company's Taiwan manufacturing facility." The FDA issued a Form 483 with ten inspectional observations. The Taiwan facility was approved for product manufacturing by the FDA in September 2009 and by Taiwan FDA in July 2010. The facility currently manufactures 12 products for distribution in the United States. On this news, shares of Impax Laboratories fell $4.23 or 15.09% during intraday trading to trade at $23.80. If you are aware of any facts relating to this investigation, or purchased shares of Impax Laboratories you can assist this investigation by contacting Edward N. Gewirtz or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.